Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
- First Online:
To evaluate the maximum tolerated dose (MTD), safety, and antitumor activity of sunitinib combined with paclitaxel and carboplatin.
Successive cohorts of patients with advanced solid tumors received oral sunitinib (25, 37.5, or 50 mg) for 2 consecutive weeks of a 3-week cycle (Schedule 2/1) or as a continuous daily dose for 3-week cycles (CDD schedule) in combination with paclitaxel (175–200 mg/m2) plus carboplatin (AUC 6 mg min/ml) on day one of each of 4 cycles. Dose-limiting toxicities (DLTs) and adverse events (AEs) were evaluated to determine the MTD. Efficacy parameters were analyzed in patients with measurable disease.
Forty-three patients were enrolled (n = 25 Schedule 2/1; n = 18 CDD schedule). Across all doses, 6 DLTs were observed [grade 4 papilledema, grade 5 GI hemorrhage, grade 3 neutropenic infection, and grade 4 thrombocytopenia (n = 3)]. The MTD for Schedule 2/1 was sunitinib 25 mg plus paclitaxel 175 mg/m2 and carboplatin AUC 6 mg min/ml. The MTD was not determined for the CDD schedule. Treatment-related AEs included neutropenia (77%), thrombocytopenia (56%), and fatigue (47%). Of 38 evaluable patients, 4 (11%) had partial responses and 12 (32%) had stable disease. PK data indicated an increase in maximum and total plasma exposures to sunitinib and its active metabolite when given with paclitaxel and carboplatin compared with sunitinib monotherapy.
Myelosuppression resulting in prolonged dose delays and frequent interruptions was observed, suggesting that this treatment combination is not feasible in the general cancer population.
KeywordsSunitinib Phase I Solid tumor NSCLC Antiangiogenesis Chemotherapy
- 2.National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: NSCLC v.2.2009. Available via http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
- 6.Robert NJ, Dieras V, Glaspy J et al (2009) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27(15s):1005 AbstractGoogle Scholar
- 12.Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMedGoogle Scholar
- 13.Motzer RJ, Hutson TE, Tomczak P et al (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 24:2sGoogle Scholar
- 14.Motzer RJ, Figlin R, Hutson TE et al (2007) Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol ASCO Annual meeting proceedings part I. vol 25, no. 18S (20 June Suppl):(Abstract 5024)Google Scholar
- 18.Rigas JR (2004) Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9 Suppl 2: 16–23Google Scholar
- 24.Kozloff M, Chuang E, Starr A et al (2010) An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 21:1436–1441Google Scholar
- 26.Chiorean EG, Sweeney CJ, Verschraegen CF et al (2008) Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): a phase I dose-finding study. J Clin Oncol 26: 2008 (20 May suppl; abstract 3562)Google Scholar
- 27.Fountzilas G, Kalofonos HP, Dafni U et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic cooperative oncology group 1. Ann Oncol 15:1517–1526PubMedCrossRefGoogle Scholar
- 28.Karp DD, Novello S, Cardenal F et al (2009) Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 27 (15s) 8072: 15s (suppl; abstract)Google Scholar
- 30.Pfizer Inc. (2008) Data on fileGoogle Scholar